Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02317783 · ClinicalTrials.gov registry record · Phase 2
Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment
A Phase 2 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT02317783 is a Phase 2 study that was terminated before completion, run by University of Utah. The registered enrollment target is 15 participants.
The verdict
NCT02317783, a Phase 2 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The initial goal of the investigators interdisciplinary group of imagers, oncologists, neurologists, neuro-psychologists, and biostatisticians is to obtain proof of concept pilot data for eventual submission of a National Cancer Institute Quick-Trial for Imaging and Image-Guided Interventions: Exploratory Grant (R10) depending on the results of this pilot study. The overall objective is to use \[18F\]Flutemetamol, FDG-PET, and fMRI to better understand CICI, which effects up to 16 -50% of individuals receiving long-term adjuvant chemotherapy.2,3 To date there have been few studies examining this problem using multi-modality imaging techniques to better understand this complex and significant problem. FDG-PET and fMRI are routinely used in clinical practice for the evaluation of cognitive dysfunction in older populations complaining of memory dysfunction. It is well recognized that FDG-PET can assist with the differentiation and characterization of various cognitive disorders due to unique patterns of cerebral metabolism caused by various cognitive and dementia-causing disorders.4-6 FDG-PET has been studied extensively in dementia research and has a high reliability in detecting Alzheimers disease (AD) many years before it can be diagnosed reliably using clinical criteria.4 To the investigators knowledge, there has been only a single small study using FDG-PET and bolus water activation paradigms in cancer patients complaining of memory problems.7 To date, there have been no studies using \[18F\]Flutemetamol as a PET imaging agent to assess the possibility of increased amyloid plaque burden as a potential contributing factor to the cognitive deficits and complaints seen in patients experiencing CICI. The novel feature of this project is in the combined use of \[18F\]Flutemetamol-PET, FDG-PET, and fMRI to study a poorly understood but common problem: cognitive impairment in breast cancer patients treated with chemotherapy. If \[18F\]Flutemetamol, FDG-PET, and fMRI
Interventions
- DIAGNOSTIC_TEST Functional Magnetic Resonance Imaging (fMRI)
- DRUG [18F]fluoro-2-deoxy-D-glucose (FDG)
- DRUG [18F]Flutemetamol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-01-31 |
| Est. Completion | 2019-09-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02317783
The ClinicalTrials.gov registry entry for NCT02317783 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Functional Magnetic Resonance Imaging (fMRI) is the first listed.
NCT02317783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02317783 about?
NCT02317783 is a clinical study titled "Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment". The initial goal of the investigators interdisciplinary group of imagers, oncologists, neurologists, neuro-psychologists, and biostatisticians is to obtain proof of concept pilot data for eventual submission of a National Cancer Institute Quick-Trial for Imaging and Image-Guided Interventions: Explo...
What is the current status of trial NCT02317783?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2018-01-31. Estimated completion is 2019-09-24.
What interventions are being tested in trial NCT02317783?
The interventions under investigation include: Functional Magnetic Resonance Imaging (fMRI) (DIAGNOSTIC_TEST), [18F]fluoro-2-deoxy-D-glucose (FDG) (DRUG), [18F]Flutemetamol (DRUG).
Who is sponsoring clinical trial NCT02317783?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.